The U.S. Food and Drug Administration (FDA) has approved Novartis‘ Kesimpta (ofatumumab) as a self-administered treatment for…
Articles by Marisa Wexler, MS
Mylan announced the launch of a first generic version of Tecfidera, a treatment for relapsing forms of…
In people with multiple sclerosis (MS), skin cells show increased amounts of cellular stress in a manner that is…
Novartis‘ ofatumumab outperformed Aubagio (teriflunomide) at lowering the frequency of relapses and preventing disability progression among people with…
Immunic Therapeutics‘s IMU-838, a selective immune system modulator, can safely lower the number of brain lesions in…
The Canadian MS Working Group (CMSWG) — made up of neurologists with the Canadian Network of MS Clinics — has…
Low doses of the anesthetic ketamine could help treat fatigue in people with multiple sclerosis (MS), according…
Assessing the cognitive health of people with multiple sclerosis (MS) can be performed using online telehealth, with results…
Treatment with Tysabri (natalizumab) can lessen disability in people with relapsing-remitting multiple sclerosis (RRMS), a large and real-world study found,…
More than half of people with brain imaging changes akin to multiple sclerosis (MS) go on to develop the…
Complementary and alternative medicines are increasingly popular among people with multiple sclerosis (MS) in the northwestern United States, a survey…
JuneBrain, a startup company that is developing a wearable head imaging device that enables multiple sclerosis (MS) patients to…
Tecfidera (dimethyl fumarate) is safe and effective as a long-term treatment for relapsing-remitting multiple sclerosis (RRMS), a study…
The National Institute for Health and Care Excellence (NICE) is recommending against Mayzent (siponimod) as a treatment for active…
A study aiming to better understand falls and fall-related injuries in people with multiple sclerosis (MS) and other neurological disorders…
A new research project will seek to understand the development of immune cells that drive autoimmune diseases such as multiple…
Icometrix launched a new digital platform, icompanion, to help people with multiple sclerosis (MS) track their disease and…
The U.S. Food and Drug Administration (FDA) is extending its review of Novartis‘Â ofatumumab, a possible self-administered injection…
Zeposia (ozanimod), a newly approved oral capsule treatment for relapsing forms of multiple sclerosis (MS), is now commercially…
Symptoms including sleep disorders and pain may precede by as many as five years the onset of the more…
A clinical trial testing Midamor (amiloride), Prozac (fluoxetine),…
The European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS)…
Higher blood levels of the neurofilament light chain (NfL) protein at diagnosis are predictive of worse disability over time in…
Note: This story was updated May 27, 2020, to note a change in the protocol of the EVOLUTION trials,…
Biogen has released new data on several of its therapies for multiple sclerosis (MS), including Vumerity (diroximel…
Glatopa, a generic form of Copaxone, is as effective as the brand-name medication in terms of disease outcomes and…
In the brains of people with advanced multiple sclerosis (MS), memory immune cells reside in the brain tissue rather…
Healthcare providers should encourage everyone with multiple sclerosis (MS) to engage in regular exercise and keep physically active, new…
A portable device that can quickly measure electrical activity in the brain and relay it to doctors via a smartphone…
Belong.Life has launched a free and anonymous social network app to offer support for people…